Kolexia
Brochet Bruno Neurologie
Brochet Bruno
Neurologie
Hôpital Pellegrin
Bordeaux, France
288 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sclérose en plaques Sclérose Sclérose en plaques récurrente-rémittente Sclérose en plaques chronique progressive Neuromyélite optique Maladies démyélinisantes Leucoencéphalopathies Leucoencéphalopathie multifocale progressive Inflammation

Collaborateurs

Voir plus
Ruet Aurelie
Ruet Aurelie
Hôpital Pellegrin, Bordeaux, France
De Sèze Jérôme
De Sèze Jérôme
Hôpital Hautepierre, Strasbourg, France
Clavelou Pierre
Clavelou Pierre
Hôpital Gabriel Montpied, Clermont-Ferrand, France
Pelletier Jean
Pelletier Jean
Hôpital La Timone, Marseille, France

Industries

Voir plus
Sanofi
36 collaboration(s)
Dernière en 2023
Novartis
18 collaboration(s)
Dernière en 2023
Celgene
9 collaboration(s)
Dernière en 2022
BMS
7 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Essai Clinique (Roche)   07 mars 2024
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis
Essai Clinique (Roche)   13 février 2024
RESPONSE: French Registry for Monitoring Pregnancies and Children of Women With Multiple Sclerosis Within The Observatoire Français de la Sclérose en Plaque (OFSEP) Cohort
Essai Clinique (Hospices Civils de Lyon)   25 janvier 2024
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis: A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Essai Clinique (Roche)   18 décembre 2023
Time to Qualifying Relapse by Previous Disease-Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets Over 2 Years in the CLARIFY-MS Study
Multiple sclerosis and related disorders   01 décembre 2023
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Multiple sclerosis (Houndmills, Basingstoke, England)   18 novembre 2023
La cognition se met à la mode : de l’IA au PIRA
Edimark   11 octobre 2023
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment.
Neurology(R) neuroimmunology & neuroinflammation   22 septembre 2023
POLAR: Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion Among Patients With or Without Lesions at the Magnetic Resonance Imaging (Oligoclonal Profile of Tears)
Essai Clinique (Lille Catholic University)   12 septembre 2023
NeurofilMS: Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Essai Clinique (CHU Nîmes)   03 mai 2023